310 related articles for article (PubMed ID: 27813535)
1. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells.
Paulus A; Akhtar S; Caulfield TR; Samuel K; Yousaf H; Bashir Y; Paulus SM; Tran D; Hudec R; Cogen D; Jiang J; Edenfield B; Novak A; Ansell SM; Witzig T; Martin P; Coleman M; Roy V; Ailawadhi S; Chitta K; Linder S; Chanan-Khan A
Blood Cancer J; 2016 Nov; 6(11):e492. PubMed ID: 27813535
[TBL] [Abstract][Full Text] [Related]
2. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.
Chitta K; Paulus A; Akhtar S; Blake MK; Caulfield TR; Novak AJ; Ansell SM; Advani P; Ailawadhi S; Sher T; Linder S; Chanan-Khan A
Br J Haematol; 2015 May; 169(3):377-90. PubMed ID: 25691154
[TBL] [Abstract][Full Text] [Related]
3. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells.
Wang X; Mazurkiewicz M; Hillert EK; Olofsson MH; Pierrou S; Hillertz P; Gullbo J; Selvaraju K; Paulus A; Akhtar S; Bossler F; Khan AC; Linder S; D'Arcy P
Sci Rep; 2016 Jun; 6():26979. PubMed ID: 27264969
[TBL] [Abstract][Full Text] [Related]
4. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.
Xu L; Tsakmaklis N; Yang G; Chen JG; Liu X; Demos M; Kofides A; Patterson CJ; Meid K; Gustine J; Dubeau T; Palomba ML; Advani R; Castillo JJ; Furman RR; Hunter ZR; Treon SP
Blood; 2017 May; 129(18):2519-2525. PubMed ID: 28235842
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Rowinsky EK; Paner A; Berdeja JG; Paba-Prada C; Venugopal P; Porkka K; Gullbo J; Linder S; Loskog A; Richardson PG; Landgren O
Invest New Drugs; 2020 Oct; 38(5):1448-1453. PubMed ID: 32125598
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Tsakmaklis N; Kanan S; Castillo JJ; Treon SP
Br J Haematol; 2015 Mar; 168(5):701-7. PubMed ID: 25371371
[TBL] [Abstract][Full Text] [Related]
7. Waldenstrom macroglobulinemia cells devoid of BTK
Paulus A; Akhtar S; Yousaf H; Manna A; Paulus SM; Bashir Y; Caulfield TR; Kuranz-Blake M; Chitta K; Wang X; Asmann Y; Hudec R; Springer W; Ailawadhi S; Chanan-Khan A
Blood Cancer J; 2017 May; 7(5):e565. PubMed ID: 28548645
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutic targets in Waldenstrom macroglobulinemia.
Paulus A; Ailawadhi S; Chanan-Khan A
Best Pract Res Clin Haematol; 2016 Jun; 29(2):216-228. PubMed ID: 27825468
[TBL] [Abstract][Full Text] [Related]
9. Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570.
Pellegrini P; Selvaraju K; Faustini E; Mofers A; Zhang X; Ternerot J; Schubert A; Linder S; D Arcy P
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32635430
[TBL] [Abstract][Full Text] [Related]
10. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Proteasome-Associated Deubiquitinating Enzyme USP14 Impairs Melanoma Cell Survival and Overcomes Resistance to MAPK-Targeting Therapies.
Didier R; Mallavialle A; Ben Jouira R; Domdom MA; Tichet M; Auberger P; Luciano F; Ohanna M; Tartare-Deckert S; Deckert M
Mol Cancer Ther; 2018 Jul; 17(7):1416-1429. PubMed ID: 29703842
[TBL] [Abstract][Full Text] [Related]
12. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
Tian Z; D'Arcy P; Wang X; Ray A; Tai YT; Hu Y; Carrasco RD; Richardson P; Linder S; Chauhan D; Anderson KC
Blood; 2014 Jan; 123(5):706-16. PubMed ID: 24319254
[TBL] [Abstract][Full Text] [Related]
13. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.
Hunter ZR; Yang G; Xu L; Liu X; Castillo JJ; Treon SP
J Clin Oncol; 2017 Mar; 35(9):994-1001. PubMed ID: 28294689
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.
Paulus A; Manna A; Akhtar S; Paulus SM; Sharma M; Coignet MV; Jiang L; Roy V; Witzig TE; Ansell SM; Allan J; Furman R; Aulakh S; Manochakian R; Ailawadhi S; Chanan-Khan AA; Sher T
Br J Haematol; 2018 Oct; 183(2):196-211. PubMed ID: 30080238
[TBL] [Abstract][Full Text] [Related]
15. Analysis of determinants for in vitro resistance to the small molecule deubiquitinase inhibitor b-AP15.
Mofers A; Perego P; Selvaraju K; Gatti L; Gullbo J; Linder S; D'Arcy P
PLoS One; 2019; 14(10):e0223807. PubMed ID: 31639138
[TBL] [Abstract][Full Text] [Related]
16. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP
Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257
[TBL] [Abstract][Full Text] [Related]
17. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Argyropoulos KV; Palomba ML
Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023
[TBL] [Abstract][Full Text] [Related]
18. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Patterson CJ; Tsakmaklis N; Kanan S; Rodig S; Castillo JJ; Treon SP
Leukemia; 2015 Jan; 29(1):169-76. PubMed ID: 24912431
[TBL] [Abstract][Full Text] [Related]
19. USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment.
Vogel RI; Pulver T; Heilmann W; Mooneyham A; Mullany S; Zhao X; Shahi M; Richter J; Klein M; Chen L; Ding R; Konecny G; Kommoss S; Winterhoff B; Ghebre R; Bazzaro M
Oncotarget; 2016 May; 7(21):30962-76. PubMed ID: 27121063
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib for the treatment of Waldenström macroglobulinemia.
Chakraborty R; Kapoor P; Ansell SM; Gertz MA
Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
